Skip to content

SAIRO - Feasibility and Safety of the Tele-operated TAVIPILOT Robot Guided by TAVIPILOT Software

SAIRO - Feasibility and Safety of the Tele-operated TAVIPILOT Robot Guided by TAVIPILOT Software During Transcatheter Aortic Valve Replacement (TAVR/TAVI)

Status
Recruiting
Phases
Unknown
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT07664163
Acronym
SAIRO
Enrollment
10
Registered
2026-06-24
Start date
2026-09-10
Completion date
2027-05-01
Last updated
2026-09-09

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

TAVI(Transcatheter Aortic Valve Implantation)

Brief summary

The TAVIPILOT robotic platform, developed by Caranx Medical is an advanced intraoperative robotic assistance system designed to enhance the precision of transcatheter aortic valve positioning during TAVR. The TAVIPILOT robotic platform includes the TAVIPILOT Software, Robot (when controlled by the user) and Loop (when guided by the Software). The system integrates with standard procedural workflows and enables remote manipulation of delivery system components, allowing for controlled, stable, and reproducible movements. TAVIPILOT devices facilitate accurate valve alignment and deployment, reducing operator variability. The robot is compatible with commercially approved balloon-expandable transcatheter heart valves (Sapien 3 and Ultra, Edwards Lifesciences, USA) and standard catheterization lab infrastructure.

Interventions

DEVICETAVR procedure with TAVIPILOT Software and tele-operated robot by Caranx Medical enhancing the precision of transcatheter aortic valve positioning during TAVR.

TAVR procedure with TAVIPILOT Software and tele-operated robot by Caranx Medical enhancing the precision of transcatheter aortic valve positioning during TAVR.

Sponsors

Caranx Medical
Lead SponsorINDUSTRY

Study design

Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT
Masking
NONE

Eligibility

Sex/Gender
ALL
Age
65 Years to No maximum
Healthy volunteers
No

Inclusion criteria

1. Patients aged ≥65 2. Indicated for transfemoral TAVR for severe aortic stenosis

Design outcomes

Primary

MeasureTime frameDescription
The investigational device-related safety will also be assessed by verifying the absence of major technical malfunctionsPeriproceduralInvestigational Device Safety
The primary objective is to evaluate investigational device-related safety, including the occurrence of investigational device-related conversion to open-heart surgery, investigational device-related valve embolization and investigational device-related.PeriproceduralInvestigational device-related safety

Secondary

MeasureTime frameDescription
Device PerformancePeriproceduralAssessment of the TAVIPILOT Robot ability to advance and retrieve the delivery system safely
Clinician satisfactionPeriproceduralThe assessment of clinician satisfaction with the investigational devices, using specific customized questionnaires

Countries

Australia

Contacts

CONTACTDr Eric Sejor
eric.sejor@caranx-medical.com09 82 24 85 61
CONTACTChristophe Naz
christophe.naz.pro@gmail.com

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Sep 10, 2026